Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival

Journal of Neuropathology and Experimental Neurology

Volumn 69, Issue 7, 2010, Pages 729-736

  McDonald, Kerrie L ^a,g   McDonnell, Julie ^a,g   Muntoni, Alessandra ^b   Henson, Jeremy D ^b,g   Hegi, Monika E ^c   Von Deimling, Andreas ^d   Wheeler, Helen R ^e   Cook, Ray J ^f   Biggs, Michael T ^f   Little, Nicholas S ^f   Robinson, Bruce G ^g   Reddel, Roger R ^b,g   Royds, Janice A ^h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e CANCER INSTITUTE NSW   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Alternative lengthening of telomeres; Glioblastoma subtypes; IDH1; Survival; Therapy

Indexed keywords

ISOCITRATE DEHYDROGENASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; IDH1 PROTEIN, HUMAN; TELOMERASE;

ADULT; AGED; ARTICLE; FEMALE; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; TELOMERE; CLINICAL TRIAL; COHORT ANALYSIS; GENETICS; INTERNATIONAL COOPERATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL; ULTRASTRUCTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; COHORT STUDIES; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; INTERNATIONAL COOPERATION; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TELOMERASE; TELOMERE; YOUNG ADULT;

EID: 77954751638     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181e576cf     Document Type: Article

References (28)

1. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts rep-licative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992; 89:10114-18
2. Colgin LM, Reddel RR. Telomere maintenance mechanisms and cellular immortalization. Curr Opin Genet Dev 1999;9:97-103
3. Blackburn EH. Telomerases. Annu Rev Biochem 1992;61:113-29
4. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006;12:1133-38
5. Shay JW, Zou Y, Hiyama E, et al. Telomerase and cancer. Hum Mol Genet 2001;10:677-85
6. Bryan TM, Englezou A, Dalla-Pozza L, et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997;3:1271-74
7. Dunham MA, Neumann AA, Fasching CL, et al. Telomere maintenance by recombination in human cells. Nat Genet 2000;26:447-50
8. Muntoni A, Neumann AA, Hills M, et al. Telomere elongation involves intra-molecular DNA replication in cells utilizing alternative lengthening of telomeres. Hum Mol Genet 2009;18:1017-27
9. Bryan TM, Englezou A, Gupta J, et al. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14: 4240-48
10. Yeager TR, Neumann AA, Englezou A, et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999;59:4175-79
11. Henson JD, Hannay JA, McCarthy SW, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005;11:217-25
12. Omori Y, Nakayama F, Li D, Kanemitsu K, et al. Alternative lengthening of telomeres frequently occurs in mismatch repair systemYdeficient gastric carcinoma. Cancer Sci 2009;100:413-18
13. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
14. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003;361:836-38
15. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63:6613-25
16. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599-601
17. Chen YJ, Hakin-Smith V, Teo M, et al. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 2006;66:6473-76
18. Henson JD, Neumann AA, Yeager TR, et al. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002;21:598-610
19. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116:597-602
20. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11:341-47
21. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17: 98-110
22. Muntoni A, Reddel RR. The first molecular details of ALT in human tumor cells. Hum Mol Genet 2005;14 Spec No. 2;R191-96
23. Li A, Walling J, Ahn S, et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 2009;69:2091-99
24. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005;102:5814-19
25. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352: 997-1003
26. Gunther HS, Schmidt NO, Phillips HS, et al. Glioblastoma-derived stem cellYenriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008;27:2897-909
27. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer 2008;98:677-83
28. Reddel RR, Bryan TM. Alternative lengthening of telomeres: dangerous road less travelled. Lancet 2003;361:1840-41